Moshkevich Solomon sold $819K of NTRA

Natera (NTRA) presented data from the ESMO Congress 2026, showcasing its Signatera assay in 25 abstracts, including 9 oral presentations. The VOLGA trial in bladder cancer showed that Signatera ctDNA dynamics predicted event-free survival, with persistently negative patients having a 24-month EFS rate of 91%. Additional studies in lung, endometrial, and breast cancer were also highlighted, demonstrating the potential of ctDNA testing in guiding treatment decisions.

Natera Inc. (NTRA) presented cancer study results at the ESMO Congress 2026, with its technology featured in 25 abstracts. Key findings included high event-free survival rates in bladder cancer, high ctDNA detection in lung cancer, and predictive value in endometrial cancer. Studies also covered colorectal and gastroesophageal cancers.

Natera (NTRA) reported phase III VOLGA trial data showing Signatera ctDNA dynamics predict event-free survival in MIBC, with 24-month EFS rates of 91% for persistently negative, 81% for cleared pre-surgery, and 55% for persistently positive. The company noted this as late-cycle validation for Signatera's role in MRD for bladder cancer.

Natera presented results from the phase III VOLGA trial, showing its Signatera assay predicted 24-month event-free survival rates of 91%, 81%, or 55% in bladder cancer patients. The assay was also highlighted in other trials for lung, endometrial, and breast cancers. Natera's tests aim to guide treatment decisions and improve outcomes.

BTIG raised its price target on Natera (NTRA) to $430 from $320, citing strong revenue growth expectations. The firm anticipates a 7% revenue beat in Q3 and projects 318,000 Signatera tests, up 57% YoY. Natera's stock is up 77% YTD and 111% over the past year, but is considered overvalued by InvestingPro. Recent Q2 revenue of $753M exceeded expectations, and multiple analysts have raised price targets.

Roth/MKM initiated Natera (NTRA) with a buy rating and $475 price target, citing its oncology diagnostics pipeline and growth potential. The stock is up 106% year-to-date. Natera's Q2 revenue exceeded expectations at $753M, prompting raised guidance. Analysts highlight MRD testing and women's health as growth drivers.